NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









IFM Therapeutics

IFM Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://ifmthera.com/

Last Round

VC Round

Dec 2, 2019

Total Funding Raised

$58M

Company Overview

IFM Therapeutics is a biopharmaceutical company that develops small molecule medicines aimed at enhancing immunotherapy by precisely targeting the innate immune system to address complex issues in treating inflammatory and autoimmune disorders as well as cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologysmall-molecule inhibitorsinnate immune systemdrug discoverybiotech incubatorNLRP3 antagonistSTING antagonistautoimmune disease therapybiotech spin-outhub-and-spoke modeldrug pipelinebiotech startupclinical-stage assetspharma licensingdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

IFM Therapeutics Comparables

Compare IFM Therapeutics with similar companies based on industry and business-model similarity.

IFM Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ventus Therapeutics
89%
Olatec Therapeutics
86%
Inflammasome Therapeutics
81%

IFM Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundDec 2, 2019
Series AJul 19, 2018
M&AAug 3, 2017
Series AJun 21, 2016
SeedOct 1, 2015

Key People

Founding team and executive leadership

Gary D. Glick

Founder, CEO, Chairman

Founding Team

H. Martin Seidel

Chief Executive Officer

Executive Team

IFM Therapeutics Investors

Notable investors and investment history

IFM Therapeutics investors
InvestorRounds
Omega FundsVC Round
AbingworthSeries A, VC Round
Atlas VentureSeries A, VC Round, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 19, 2018

    $31M round with participation from Abingworth and Atlas Venture.

  • Jun 21, 2016

    $27M round led by Abingworth and Atlas Venture.

IFM Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

IFM Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about IFM Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range11
Year Founded2015
Last FundingDec 2, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.